
RHHBF
Healthcare · Drug Manufacturers - General · $382.42B market cap
$483.07-13.86 (-2.8%)Nov 13, 3:48 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 21, 2021 | After the close | 0.00 | 4.89 | — |
| Feb 4, 2021 | After the close | 0.00 | 4.79 | — |
| Oct 15, 2020 | After the close | 0.00 | 4.06 | — |
| Jul 23, 2020 | Before the open | 0.00 | 3.90 | — |
| Apr 22, 2020 | Before the open | 0.00 | 4.92 | — |
| Jan 29, 2020 | After the close | 0.00 | 4.85 | — |
| Oct 16, 2019 | After the close | 0.00 | 2.91 | — |
| Jul 25, 2019 | After the close | 0.00 | 2.82 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | 5.11 | — |
| Jan 30, 2019 | After the close | 0.00 | 5.01 | — |
| Oct 25, 2018 | Before the open | 0.00 | 1.89 | — |
| Jul 25, 2018 | After the close | 0.00 | 1.89 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | 4.30 | — |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It…
| After the close |
| 0.00 |
| 4.46 |
| — |